118 related articles for article (PubMed ID: 16093429)
1. Murine double minute 2 as a therapeutic target for radiation sensitization of lung cancer.
Cao C; Shinohara ET; Niermann KJ; Donnelly EF; Chen X; Hallahan DE; Lu B
Mol Cancer Ther; 2005 Aug; 4(8):1137-45. PubMed ID: 16093429
[TBL] [Abstract][Full Text] [Related]
2. Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence.
Luo H; Yount C; Lang H; Yang A; Riemer EC; Lyons K; Vanek KN; Silvestri GA; Schulte BA; Wang GY
Lung Cancer; 2013 Aug; 81(2):167-73. PubMed ID: 23683497
[TBL] [Abstract][Full Text] [Related]
3. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Wang H; Yu D; Agrawal S; Zhang R
Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
[TBL] [Abstract][Full Text] [Related]
4. Clusterin as a therapeutic target for radiation sensitization in a lung cancer model.
Cao C; Shinohara ET; Li H; Niermann KJ; Kim KW; Sekhar KR; Gleave M; Freeman M; Lu B
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1228-36. PubMed ID: 16253777
[TBL] [Abstract][Full Text] [Related]
5. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models.
Zhang Z; Wang H; Prasad G; Li M; Yu D; Bonner JA; Agrawal S; Zhang R
Clin Cancer Res; 2004 Feb; 10(4):1263-73. PubMed ID: 14977824
[TBL] [Abstract][Full Text] [Related]
6. Transfection with mdm2-antisense or wtp53 results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line.
Grünbaum U; Meye A; Bache M; Bartel F; Würl P; Schmidt H; Dunst J; Taubert H
Anticancer Res; 2001; 21(3B):2065-71. PubMed ID: 11497299
[TBL] [Abstract][Full Text] [Related]
7. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
8. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
9. MDM2 oncogene as a target for cancer therapy: An antisense approach.
Wang H; Zeng X; Oliver P; Le LP; Chen J; Chen L; Zhou W; Agrawal S; Zhang R
Int J Oncol; 1999 Oct; 15(4):653-60. PubMed ID: 10493945
[TBL] [Abstract][Full Text] [Related]
10. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.
Cao C; Shinohara ET; Subhawong TK; Geng L; Kim KW; Albert JM; Hallahan DE; Lu B
Mol Cancer Ther; 2006 Feb; 5(2):411-7. PubMed ID: 16505116
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms.
Wang H; Nan L; Yu D; Lindsey JR; Agrawal S; Zhang R
Mol Med; 2002 Apr; 8(4):185-99. PubMed ID: 12149568
[TBL] [Abstract][Full Text] [Related]
12. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer.
Cao C; Mu Y; Hallahan DE; Lu B
Oncogene; 2004 Sep; 23(42):7047-52. PubMed ID: 15258565
[TBL] [Abstract][Full Text] [Related]
13. Survivin as a therapeutic target for radiation sensitization in lung cancer.
Lu B; Mu Y; Cao C; Zeng F; Schneider S; Tan J; Price J; Chen J; Freeman M; Hallahan DE
Cancer Res; 2004 Apr; 64(8):2840-5. PubMed ID: 15087401
[TBL] [Abstract][Full Text] [Related]
14. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
15. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme.
Prasad G; Wang H; Agrawal S; Zhang R
Anticancer Res; 2002; 22(1A):107-16. PubMed ID: 12017271
[TBL] [Abstract][Full Text] [Related]
16. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells.
Sun Y; Sun D; Li F; Tian L; Li C; Li L; Lin R; Wang S
Lung Cancer; 2007 Oct; 58(1):21-9. PubMed ID: 17624472
[TBL] [Abstract][Full Text] [Related]
18. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
19. An anthraquinone derivative from Luffa acutangula induces apoptosis in human lung cancer cell line NCI-H460 through p53-dependent pathway.
Vanajothi R; Srinivasan P
J Recept Signal Transduct Res; 2016; 36(3):292-302. PubMed ID: 26585176
[TBL] [Abstract][Full Text] [Related]
20. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy.
Zhang Z; Li M; Wang H; Agrawal S; Zhang R
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11636-41. PubMed ID: 13130078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]